Sagent Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sagent Pharmaceuticals Inc.
Down But Not Out: Nichi-Iko Hives Off Sagent, Exits North America
Seven years after it paid almost three quarters of a billion dollars for US-based Sagent, troubled Nichi-Iko is offloading the struggling business.
Nichi-Iko Secures Up To ¥98.5bn Debt Relief As ADR Pushes Ahead
Troubled Japanese firm Nichi-Iko has currently has ¥55.8bn of debt forgiveness, which may expand to ¥98.5bn in the future. It currently faces regular payments until 2033 to settle all of its debts.
Earnings Recovery For Nichi-Iko Unlikely Before Full Resumption Of Toyama Shipments
Nichi-Iko still has a long road to recovery ahead as it attempts to get its Toyama plant back on its feet.
China First Domestic COVID-19 Antibody Therapy Moves Towards Green Light
Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.
- Generic Drugs
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.